The article states that clinical literature does not establish that GLP-1 agonists treat Hashimoto's or reduce thyroid antibody levels, and that no randomized trials have evaluated semaglutide or tirzepatide as a primary treatment for it
For instance, in phase 2 trials of SEMA 2.4 g, a substantial reduction in placebo response was observed in composite endpoints of MASH and fibrosis
dosing errors from patients self-administering incorrect amounts from multidose vials a risk inherent to the compounded product format rather than the active ingredient itself

A conceptual model of food cue reactivity, Nutrients (2023) Human drug compounding, Food and Drug Administration (2024) Compounding when drugs are on FDAs drug shortages list, Food and Drug Administration (2024) Your guide to FDA-approved medicines that contain semaglutide, Novo Nordisk FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food & Drug Administration (2024) Wegovy, DailyMed (2024) FDA warns patients and health care professionals not to use compounded drugs from Fullerton Wellness, Food and Drug Administration (2024) Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs, Novo Nordisk (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) OFA v

Secondary PK endpoints after the first dose of semaglutide (single dose) included AUC 0168 h,SD , C max,SD and t max,SD